Parkwood LLC Vaxcyte, Inc. Transaction History

Parkwood LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$60.06 - $78.77 $111,291 - $145,960	-1,853 Reduced 13.67%	11,702 $884,000
Q1 2024 May 15, 2024	SELL	$59.79 - $81.05 $115,095 - $156,021	-1,925 Reduced 12.44%	13,555 $926,000
Q4 2023 Feb 14, 2024	SELL	$45.35 - $63.41 $52,651 - $73,619	-1,161 Reduced 6.98%	15,480 $972,000
Q3 2023 Nov 14, 2023	BUY	$46.0 - $53.1 $85,698 - $98,925	1,863 Added 12.61%	16,641 $848,000
Q2 2023 Aug 14, 2023	SELL	$34.66 - $54.07 $75,454 - $117,710	-2,177 Reduced 12.84%	14,778 $738,000
Q1 2023 May 15, 2023	BUY	$36.27 - $47.2 $349,533 - $454,866	9,637 Added 131.69%	16,955 $635,000
Q4 2022 Feb 14, 2023	SELL	$20.58 - $47.95 $101,665 - $236,873	-4,940 Reduced 40.3%	7,318 $351,000
Q3 2022 Nov 14, 2022	BUY	$21.69 - $28.53 $7,548 - $9,928	348 Added 2.92%	12,258 $294,000
Q2 2022 Aug 15, 2022	BUY	$17.68 - $26.58 $210,568 - $316,567	11,910 New	11,910 $12,000
Q1 2021 May 14, 2021	SELL	$18.66 - $29.16 $526,044 - $822,049	-28,191 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$26.57 - $51.74 $749,034 - $1.46 Million	28,191 New	28,191 $749,000

352

122M

775K

433K

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $5.25B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

Get notified when there are updates to the investment portfolio of Parkwood LLC, based on Form 13F filings with the SEC.

Stay updated on Parkwood LLC with notifications on news.